Two randomised, placebo-controlled, double-masked, multicentre, #-month studies (BPD OCR # AMD, or Verteporfin in Photodynamic Therapy-AMD [ VIP-AMD ], and BPD OCR #, or Visudyne in Occult Choroidal Neovascularisation [ VIO ]) were conducted in patients with AMD characterised by occult with no classic subfoveal CNV
Två randomiserade, placebokontrollerade, dubbelblinda, multicenter, #-månadersstudier (BPD OCR # AMD, eller Verteporfin in Photodynamic Therapy-AMD [ VIP-AMD ], och BPD OCR #, eller Visudyne in Occult Choroidal Neovascularization [ VIO ]) på patienter med AMD kännetecknad av ockult utan klassisk subfoveal CNVEMEA0.3 EMEA0.3